+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Graft Versus Host Disease Treatment Market by Treatment Class, Route of Administration, Disease Type, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Graft Versus Host Disease Treatment Market by Treatment Class, Route of Administration, Disease Type, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Graft Versus Host Disease Treatment Market by Treatment Class, Route of Administration, Disease Type, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5532915
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Graft Versus Host Disease Treatment Market is projected to reach USD 2.50 Billion in 2026. It is expected to continue growing at a CAGR of 10.83%, reaching USD 4.70 Billion by 2032.

Graft versus host disease (GVHD) treatment is a critical component of allogeneic hematopoietic stem cell transplantation care, addressing immune-mediated tissue injury that can affect the skin, gastrointestinal tract, liver, lungs, eyes, oral mucosa, fascia, and other organs. Acute and chronic GVHD remain major causes of post-transplant morbidity and non-relapse mortality, making prevention, early diagnosis, infection-aware immunosuppression, and steroid-sparing therapy central to clinical strategy.

The GVHD treatment landscape is shifting from broad immunosuppression toward targeted immunomodulation, evidence-based prophylaxis, organ-directed supportive care, and longitudinal survivorship management. Corticosteroids remain the standard first-line therapy for many patients, while approved options such as ruxolitinib, belumosudil, ibrutinib, and abatacept have expanded treatment and prevention pathways for defined acute and chronic GVHD populations, supported by regulatory approvals and clinical guideline incorporation.

Transformative Shifts in the GVHD Treatment Landscape

The GVHD treatment landscape is being transformed by pathway-specific therapies, improved donor selection, optimized conditioning regimens, enhanced infection prophylaxis, and growing use of post-transplant cyclophosphamide in haploidentical and matched donor settings. Clinical practice is increasingly focused on balancing graft-versus-leukemia activity with immune tolerance to reduce treatment-related toxicity while preserving disease-control benefits after allogeneic transplantation.

Another major shift is the movement toward earlier risk identification and organ-specific management. Biomarker research, microbiome science, extracorporeal photopheresis, JAK inhibition, ROCK2 inhibition, BTK inhibition, calcineurin inhibitor optimization, and costimulation blockade are reshaping how clinicians sequence therapies and manage steroid-refractory or steroid-dependent disease. This evolution is also increasing the importance of multidisciplinary care across hematology, dermatology, gastroenterology, pulmonology, ophthalmology, infectious disease, pharmacy, rehabilitation, and patient-reported outcome monitoring.

Cumulative Impact of Artificial Intelligence in GVHD Care

Artificial intelligence is beginning to influence GVHD treatment through predictive modeling, clinical decision support, trial matching, pharmacovigilance, and real-world evidence generation. AI-enabled analysis of electronic health records, laboratory trends, immunosuppressant exposure, pathology images, genomics, microbiome data, transplant variables, and patient-reported outcomes can help identify patients at higher risk for severe acute or chronic GVHD and support earlier escalation or de-escalation decisions.

The cumulative impact of AI is expected to be strongest where transplant centers maintain high-quality longitudinal datasets and harmonized outcome definitions. Responsible adoption requires transparent algorithms, external validation across diverse populations, privacy safeguards, bias monitoring, clinician oversight, and alignment with regulatory expectations for software used in clinical care. In GVHD treatment, AI is most valuable when it improves risk stratification, supports timely intervention, and strengthens evidence generation without replacing specialist clinical judgment.

Key Regional Insights for GVHD Treatment

Asia-Pacific is expanding its GVHD treatment relevance as transplant activity, donor registries, and specialty hematology infrastructure advance across China, Japan, India, South Korea, and Australia, although access to advanced therapies varies widely by reimbursement, urban specialty-center concentration, and medicine availability. North America remains a highly developed region for GVHD treatment due to established allogeneic transplant programs, FDA-approved GVHD therapies, active clinical trial participation, transplant registry depth, and payer pathways that support adoption of specialty medicines when evidence and coverage criteria are met.

Europe benefits from coordinated transplant networks, EMA oversight, national reimbursement systems, and strong academic transplant centers across the United Kingdom, Germany, France, Italy, and Spain, supporting guideline-driven use of prophylaxis, systemic therapy, and supportive care. Latin America is led by Brazil and Mexico, where major urban hospitals deliver specialist transplant services, but affordability, reimbursement variability, and access to newer immunomodulators continue to shape treatment selection. The Middle East is advancing through tertiary-care investment, especially in GCC health systems, while Africa remains constrained by limited transplant capacity, workforce gaps, diagnostic access challenges, and uneven availability of immunosuppressive and infection-management medicines.

Key Group Insights Across Major Economic Alliances

ASEAN countries show rising interest in hematology transplantation as tertiary hospitals expand oncology and transplant capabilities, but reimbursement gaps, uneven specialty-center density, and variable access to advanced GVHD medicines limit broad adoption. The GCC is prioritizing transplant program development through hospital investment, national specialty-care strategies, medical travel reduction, and access to high-cost specialty medicines in leading centers, making GVHD prevention and post-transplant care increasingly relevant to regional hematology planning.

The European Union supports harmonized regulatory oversight, pharmacovigilance, cross-border research collaboration, and evidence generation through mature transplant networks, while BRICS countries offer scale, expanding clinical capacity, and growing domestic biopharmaceutical participation, with access patterns differing substantially across members. G7 countries remain central to GVHD innovation, clinical guideline development, regulatory evaluation, and uptake of advanced therapies. NATO countries, particularly in Europe and North America, benefit from mature healthcare systems, resilient medicine supply planning, advanced clinical networks, and established transplant infrastructure that support evidence-based GVHD care delivery.

Key Country Insights for GVHD Treatment

The United States leads GVHD therapy adoption through FDA approvals, extensive transplant networks, registry-supported evidence, and active clinical research, while Canada emphasizes guideline-based access within publicly funded healthcare systems and centralized specialty care. Mexico and Brazil are key Latin American countries where major urban transplant centers drive specialist care, but affordability, reimbursement pathways, medicine availability, and patient travel requirements influence GVHD treatment choice and continuity of follow-up.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine transplant expertise with structured reimbursement, clinical guideline adoption, and academic research participation, while Russia maintains demand through large tertiary centers and specialized hematology services. China and India are expanding transplant access through increasing hematology capacity and growing clinical expertise, though regional disparities remain important. Japan and South Korea emphasize high-quality specialty care, innovation, registry-informed practice, and strong hospital infrastructure, while Australia benefits from established transplant services, national clinical governance, and integration with international evidence in acute and chronic GVHD management.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based positioning, differentiated clinical value, and real-world outcomes that demonstrate durable response, steroid reduction, infection risk management, organ-specific benefit, functional improvement, and quality-of-life gains. Partnerships with transplant centers, academic networks, patient registries, and clinical societies can strengthen evidence generation and support payer discussions focused on medically meaningful outcomes rather than short-term response alone.

Organizations should also invest in biomarker-enabled development, AI-ready data infrastructure, patient support programs, adherence resources, education for multidisciplinary teams, and region-specific access strategies. Competitive advantage will come from therapies and care models that fit transplant workflows, address steroid-refractory and steroid-dependent disease, support both acute and chronic GVHD pathways, and demonstrate safe use alongside antimicrobial prophylaxis, vaccination planning, and long-term survivorship care.

Research Methodology

This executive summary is based on validated secondary research from regulatory databases, clinical trial registries, transplant society guidance, peer-reviewed literature, and publicly available information from hematology, oncology, immunology, and transplant organizations. Sources considered include recognized regulatory bodies, transplant registries, clinical practice guidelines, prescribing information, consensus publications, and evidence from controlled studies and real-world clinical practice reports.

Insights were developed through triangulation of therapy approvals, clinical adoption trends, regional healthcare infrastructure, transplant-care standards, access conditions, and disease-management protocols. Emphasis was placed on verified developments, including approved GVHD medicines, established prophylaxis and treatment practices, documented differences in specialized hematology access, and evidence-backed regional variations in transplant infrastructure. Market estimation, market sizing, market share, and forecasting were intentionally excluded.

Conclusion

GVHD treatment is entering a more targeted, evidence-driven, and data-enabled era as clinicians move beyond generalized immunosuppression toward precision-oriented disease control. Approved targeted therapies, improved prophylaxis, biomarker research, multidisciplinary supportive care, and stronger survivorship management are reshaping treatment pathways for allogeneic transplant recipients with acute and chronic GVHD.

Future progress will depend on clinical differentiation, equitable access, biomarker validation, infection-aware treatment sequencing, and responsible integration of AI into transplant medicine. Organizations that align innovation with real-world evidence, regional affordability, regulatory expectations, and specialist workflow needs will be best positioned to support better outcomes in the evolving GVHD treatment landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Graft Versus Host Disease Treatment Market, by Treatment Class
7.1. Calcineurin Inhibitors
7.2. Corticosteroids
7.3. JAK Inhibitors
7.4. Monoclonal Antibodies
8. Graft Versus Host Disease Treatment Market, by Route Of Administration
8.1. Intravenous
8.2. Oral
8.3. Subcutaneous
9. Graft Versus Host Disease Treatment Market, by Disease Type
9.1. Acute GvHD
9.2. Chronic GvHD
10. Graft Versus Host Disease Treatment Market, by End User
10.1. Ambulatory Care Centers
10.2. Hospitals
10.3. Specialty Clinics
11. Graft Versus Host Disease Treatment Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Asia-Pacific Graft Versus Host Disease Treatment Market
13. North America Graft Versus Host Disease Treatment Market
14. Latin America Graft Versus Host Disease Treatment Market
15. Europe Graft Versus Host Disease Treatment Market
16. Middle East Graft Versus Host Disease Treatment Market
17. Africa Graft Versus Host Disease Treatment Market
18. ASEAN Graft Versus Host Disease Treatment Market
19. GCC Graft Versus Host Disease Treatment Market
20. European Union Graft Versus Host Disease Treatment Market
21. BRICS Graft Versus Host Disease Treatment Market
22. G7 Graft Versus Host Disease Treatment Market
23. NATO Graft Versus Host Disease Treatment Market
24. United States Graft Versus Host Disease Treatment Market
25. Canada Graft Versus Host Disease Treatment Market
26. Mexico Graft Versus Host Disease Treatment Market
27. Brazil Graft Versus Host Disease Treatment Market
28. United Kingdom Graft Versus Host Disease Treatment Market
29. Germany Graft Versus Host Disease Treatment Market
30. France Graft Versus Host Disease Treatment Market
31. Russia Graft Versus Host Disease Treatment Market
32. Italy Graft Versus Host Disease Treatment Market
33. Spain Graft Versus Host Disease Treatment Market
34. China Graft Versus Host Disease Treatment Market
35. India Graft Versus Host Disease Treatment Market
36. Japan Graft Versus Host Disease Treatment Market
37. Australia Graft Versus Host Disease Treatment Market
38. South Korea Graft Versus Host Disease Treatment Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. Abbott Laboratories
40.2. AbbVie Inc.
40.3. Allergan PLC by AbbVie Inc.
40.4. Amgen Inc.
40.5. Astellas Pharma Inc.
40.6. AstraZeneca PLC
40.7. Biogen Inc.
40.8. Boehringer Ingelheim GmbH
40.9. Bristol Myers Squibb Company
40.10. Cipla Inc.
40.11. Dr. Reddy's Laboratories Ltd.
40.12. Eli Lilly and Company
40.13. ElsaLyn Biopharma Inc.
40.14. Equillium, Inc.
40.15. Galderma Group
40.16. Gilead Sciences, Inc.
40.17. GlaxoSmithKline PLC
40.18. Incyte Corporation
40.19. Janssen Pharmaceuticals, Inc.
40.20. Kadmon Corporation, LLC
40.21. Lupin Pharmaceuticals, Inc.
40.22. Mallinckrodt plc
40.23. Merck & Co., Inc.
40.24. Mesoblast Limited
40.25. Novartis AG
40.26. Omeros Corporation
40.27. Pfizer Inc.
40.28. Sanofi S.A.
40.29. SANTHERA PHARMACEUTICALS
40.30. Sobi AB
40.31. Sun Pharmaceutical Industries Ltd.
40.32. Takeda Pharmaceutical Company Limited
40.33. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 23. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. NORTH AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. NORTH AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. LATIN AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. LATIN AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. EUROPE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. EUROPE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. MIDDLE EAST GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. MIDDLE EAST GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. ASEAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. ASEAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. GCC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. GCC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. EUROPEAN UNION GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. EUROPEAN UNION GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. G7 GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. G7 GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. NATO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. NATO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL JAK INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL JAK INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL JAK INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ACUTE GVHD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ACUTE GVHD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ACUTE GVHD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CHRONIC GVHD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CHRONIC GVHD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CHRONIC GVHD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 60. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 61. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 62. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 63. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 64. NORTH AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. NORTH AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 66. NORTH AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 68. NORTH AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 69. NORTH AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 70. LATIN AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. LATIN AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 72. LATIN AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 73. LATIN AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 74. LATIN AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 75. LATIN AMERICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 76. EUROPE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. EUROPE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 78. EUROPE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 79. EUROPE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 80. EUROPE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 81. EUROPE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. MIDDLE EAST GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. MIDDLE EAST GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 84. MIDDLE EAST GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 85. MIDDLE EAST GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 86. MIDDLE EAST GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 87. MIDDLE EAST GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 90. AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 91. AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 92. AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 93. AFRICA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 94. ASEAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. ASEAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 96. ASEAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 97. ASEAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 98. ASEAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 99. ASEAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 100. GCC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GCC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 102. GCC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 103. GCC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 104. GCC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. GCC GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 106. EUROPEAN UNION GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. EUROPEAN UNION GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 108. EUROPEAN UNION GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 109. EUROPEAN UNION GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 110. EUROPEAN UNION GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. EUROPEAN UNION GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 112. BRICS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. BRICS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 114. BRICS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 115. BRICS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 116. BRICS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 117. BRICS GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. G7 GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 119. G7 GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 120. G7 GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 121. G7 GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 122. G7 GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 123. G7 GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 124. NATO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. NATO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 126. NATO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 127. NATO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 128. NATO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 129. NATO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 130. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 131. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 132. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 133. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 134. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 135. UNITED STATES GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 137. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 138. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 139. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 140. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 141. CANADA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 142. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 143. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 144. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 145. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 146. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 147. MEXICO GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 148. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 149. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 150. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 151. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 152. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 153. BRAZIL GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 154. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 155. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 156. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 157. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 158. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. UNITED KINGDOM GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 160. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 161. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 162. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 164. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 165. GERMANY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 167. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 168. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 169. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 170. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. FRANCE GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 172. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 173. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 174. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 175. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 176. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. RUSSIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 178. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 179. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 180. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 181. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 182. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 183. ITALY GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 185. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 186. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 187. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 188. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 189. SPAIN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 190. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 191. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 192. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 193. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 194. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. CHINA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 196. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 197. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 198. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 200. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. INDIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 202. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 203. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 204. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 205. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 206. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 207. JAPAN GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 208. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 209. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 210. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 211. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 212. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 213. AUSTRALIA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 214. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 215. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2032 (USD MILLION)
TABLE 216. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 217. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
TABLE 218. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 219. SOUTH KOREA GRAFT VERSUS HOST DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Graft Versus Host Disease Treatment market report include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Allergan PLC by AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol Myers Squibb Company
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • ElsaLyn Biopharma Inc.
  • Equillium, Inc.
  • Galderma Group
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Janssen Pharmaceuticals, Inc.
  • Kadmon Corporation, LLC
  • Lupin Pharmaceuticals, Inc.
  • Mallinckrodt plc
  • Merck & Co., Inc.
  • Mesoblast Limited
  • Novartis AG
  • Omeros Corporation
  • Pfizer Inc.
  • Sanofi S.A.
  • SANTHERA PHARMACEUTICALS
  • Sobi AB
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages181
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.5 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.7 Billion
Compound Annual Growth Rate10.8%
Regions CoveredGlobal
No. of Companies Mentioned34

Related Topics

Related Reports

Graft Versus Host Disease (GvHD) Treatment - Global Strategic Business Report - Product Image

Graft Versus Host Disease (GvHD) Treatment - Global Strategic Business Report

  • Report
  • 296 Pages
  • Global
From
Graft Versus Host Disease (GVHD) Treatment Market Report 2026 - Product Image

Graft Versus Host Disease (GVHD) Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Graft Versus Host Disease Market - A Global and Regional Analysis: Focus on Country and Region, 2025-2035 - Product Image

Graft Versus Host Disease Market - A Global and Regional Analysis: Focus on Country and Region, 2025-2035

  • Report
  • Global
From
Graft Versus Host Disease (GVHD) Epidemiology Forecast 2025-2034 - Product Image

Graft Versus Host Disease (GVHD) Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From
Steroid Refractory Acute Graft Versus Host Disease Pipeline Analysis Report 2025 - Product Image

Steroid Refractory Acute Graft Versus Host Disease Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From

About the Graft Versus Host Disease Drug Market

Graft Versus Host Disease (GVHD) is a type of immune disorder that occurs when transplanted donor cells attack the recipient's body. It is a common complication of bone marrow and stem cell transplants. Treatment for GVHD typically involves immunosuppressive drugs, such as corticosteroids, calcineurin inhibitors, and monoclonal antibodies. These drugs are used to reduce inflammation and suppress the immune system, allowing the body to accept the donor cells. The GVHD drug market is a rapidly growing segment of the immune disorder drug market. It is driven by the increasing prevalence of GVHD, as well as the development of new drugs and treatments. The market is expected to continue to grow in the coming years, as more treatments become available and the demand for GVHD drugs increases. Some of the major companies in the GVHD drug market include Novartis, Celgene, Gilead Sciences, and Bristol-Myers Squibb. These companies are involved in the development and marketing of GVHD drugs, as well as other immune disorder drugs. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.